SS-31 vs Vesilute
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Elamipretide, Bendavia
SS-31 (sequence D-Arg-Dmt-Lys-Phe-NH2), known generically as elamipretide and sold as FORZINITY, is a synthetic tetrapeptide that homes in on the energy-producing machinery inside your cells. It works by binding cardiolipin, a fat unique to the inner mitochondrial membrane, to help mitochondria run cleaner and make more ATP with less oxidative damage. This is the rare research peptide with a real regulatory finish line: the FDA granted it accelerated approval in September 2025 for Barth syndrome, though it has failed several other major trials.
Also: ED Dipeptide, Glu-Asp
Vesilute is marketed as a Khavinson-style short peptide bioregulator aimed at the urinary bladder and lower urinary tract. Vendor sources cannot even agree on its sequence: some list a Glu-Asp dipeptide, others a Lys-Glu-Asp tripeptide. There are no approvals and, importantly, no peer-reviewed studies published specifically on a peptide called Vesilute, so almost everything written about it is extrapolated from the broader bioregulator family rather than direct evidence.
Key Comparison Insights
- SS-31 is FDA approved, while Vesilute remains in research stages.
- Both peptides belong to the Anti-Aging category, suggesting similar primary applications.
- SS-31 has stronger research evidence (FDA Approved) compared to Vesilute (Preclinical).
Detailed Comparison
| Attribute | SS-31 | Vesilute |
|---|---|---|
| Category | Anti-Aging | Anti-Aging |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | SS-31 is a cell-permeable, mitochondria-targeted peptide that concentrates in the inner mitochondrial membrane and binds tightly to cardiolipin. Cardiolipin is essential for keeping the membrane's folded cristae structure intact and for organizing the proteins of the electron transport chain that generate ATP. By stabilizing cardiolipin, SS-31 helps preserve cristae shape, reduces the electron leakage that produces reactive oxygen species, and supports more efficient ATP production. Studies also suggest it modulates the membrane's surface electrostatics and can limit opening of the mitochondrial permeability transition pore, a trigger for cell death, though the full mechanistic picture is still being worked out. | The claimed mechanism is the generic Khavinson one applied to bladder tissue: a very small peptide that can enter the cell nucleus, interact with chromatin and gene promoter regions, and adjust the expression of genes involved in bladder wall and smooth-muscle function. The marketing narrative adds heterochromatin decondensation, reactivation of genes silenced with age, and reduced chronic inflammation. None of this is supported by published experiments on this specific compound. Treat the entire mechanism as an unverified hypothesis borrowed from related peptides, not an established pathway for Vesilute itself. |
| Common Dosing | 40 mg subcutaneous daily Once daily | 1-2 capsules (10-20 mg) daily 1-2x daily, before meals |
| Administration | Subcutaneous injection or IV infusion | Oral capsules |
| Typical Duration | Variable by condition | 30-day courses, repeat after 4-6 months |
| Best Time to Take | Morning | Morning, before meals |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Unlike most peptides in this space, SS-31 has been through extensive human trials, with a mixed but consequential record. In TAZPOWER, a randomized placebo-controlled crossover study in Barth syndrome, elamipretide improved skeletal muscle strength and cardiac stroke volume, and the long open-label extension showed sustained benefit, which ultimately supported FDA accelerated approval in September 2025 as the first treatment for that ultra-rare disease. It has also failed prominently: the Phase 3 MMPOWER-3 trial in primary mitochondrial myopathy missed its primary endpoints on the six-minute walk test, the ReCLAIM trial in dry age-related macular degeneration did not hit its primary endpoints, and a heart-failure trial (PROGRESS-HF) also missed its primary endpoint. Across these studies the drug was generally well tolerated, with mostly mild effects such as injection-site reactions, headache and nausea. The accurate summary is that SS-31 is a validated mitochondrial-targeting peptide with one approved indication and a string of negative trials elsewhere, so its benefit appears to depend heavily on the specific disease. | This is where Vesilute falls apart on scrutiny. A literature search turns up no controlled studies, no animal data, and no human trials carried out on a peptide named Vesilute. The supportive-sounding claims about bladder and prostate function are reasoned by analogy from other Khavinson cytomedin and cytogen peptides, which themselves rest largely on a single research lineage with limited independent replication. Because even the basic sequence is reported inconsistently across suppliers, you cannot be confident two products labeled Vesilute are the same molecule. There is no safety or efficacy evidence to support using it for urinary symptoms, bladder health, or anything else. Anyone presenting Vesilute as proven is overstating an almost entirely unstudied product. |
Frequently Asked Questions: SS-31 vs Vesilute
What is the difference between SS-31 and Vesilute?
SS-31 is a anti-aging peptide that ss-31 (sequence d-arg-dmt-lys-phe-nh2), known generically as elamipretide and sold as forzinity, is a synthetic tetrapeptide that homes in on the energy-producing machinery inside your cells. it works by binding cardiolipin, a fat unique to the inner mitochondrial membrane, to help mitochondria run cleaner and make more atp with less oxidative damage. this is the rare research peptide with a real regulatory finish line: the fda granted it accelerated approval in september 2025 for barth syndrome, though it has failed several other major trials. Vesilute is a anti-aging peptide that vesilute is marketed as a khavinson-style short peptide bioregulator aimed at the urinary bladder and lower urinary tract. vendor sources cannot even agree on its sequence: some list a glu-asp dipeptide, others a lys-glu-asp tripeptide. there are no approvals and, importantly, no peer-reviewed studies published specifically on a peptide called vesilute, so almost everything written about it is extrapolated from the broader bioregulator family rather than direct evidence. The main differences lie in their mechanisms of action and clinical applications.
Which is better, SS-31 or Vesilute?
Neither is universally "better" - the choice depends on your specific goals. SS-31 is typically used for anti-aging purposes, while Vesilute is used for anti-aging. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can SS-31 and Vesilute be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using SS-31 and Vesilute together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.